Oncolytics Biotech
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Oncolytics Biotech sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Oncolytics Biotech: 12 sponsored US clinical trials, 1 recruiting.
Oncolytics Biotech sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Squamous Cell of the Head and Neck, with 1 trials.
Top-decile sponsor footprint
Oncolytics Biotech ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
12 total, page 1 of 1
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
NCT04215146
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
NCT02620423
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
NCT01274624
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
NCT01166542
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
NCT00998322
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
NCT00998192
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
NCT00984464
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
NCT00861627
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
NCT00753038
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
NCT00503295
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
NCT00528684
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Oncolytics Biotech pipeline
1 recruiting of 12 indexed (8% open); 10 completed (83%).
Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Carcinoma, Squamous Cell of the Head and Neck (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oncolytics Biotech: open-pipeline peers nationwide
Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Oncolytics Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
- Boston VA Research Institute · 8% recruiting · 12 trials
Related
What to do with this Oncolytics Biotech page
12 registered trials is a research-attention snapshot, not an endorsement of Oncolytics Biotech or any single study.
- 1 of Oncolytics Biotech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Carcinoma, Squamous Cell of the Head and Neck is the condition Oncolytics Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Squamous Cell of the Head and Neck trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Oncolytics Biotech pipeline card: 12 registered trials from official public datasets.Report a data error.